Tag: Richard Furman MD

The Weill Cornell Lymphoma Program has recently opened a new clinical trial for men and women with chronic lymphocytic leukemia. The study sponsor is Gilead Sciences, Inc., and the principal investigator at Weill Cornell is Richard Furman, M.D..  For more information about the study, please call Amelyn Rodgriguez, RN at (212) 746-1362 or e-mail Amelyn at amr2017@med.cornell.edu.

Key Eligibility

• Men and women age 18 and older
• Diagnosis of CLL with 17p deletion
• No prior therapy for CLL other than corticosteroids for disease complications
• Detailed eligibility reviewed when you contact the study team

Study Details

This clinical trial is for men and women with previously untreated CLL with 17p Deletion.

Patients with 17p deleted CLL have particularly aggressive courses characterized by a lack of response to chemotherapy.  Standard treatment for patients who are previously untreated is chemotherapy that carries significant risks without the likelihood of significant benefit. Idelalisib has demonstrated excellent activity and tolerability in patients with relapsed and refractory 17p deleted CLL. This study will provide more information about whether giving rituximab and idelalisib together can benefit patients with previously untreated CLL who have a 17p deletion.

Subjects will receive rituximab for 8 weeks and Idelalisib continuously throughout the study (up to 10 years) as long as they are responding to therapy and not experiencing unacceptable side effects. Rituximab is administered intravenously once weekly. Idelalisib is administered orally twice daily. After discontinuing treatment, follow-up information will be collected once every year throughout the study (up to 10 years) at clinic visits or through telephone calls.

Subjects will be provided a stipend for each study visit to reimburse the cost of travel and other expenses.